RESUMO
The ideal immunological target for cancer vaccine development would meet the criteria of tumor specificity, immunogenicity and vital dependency of the tumor on the functional activities of the antigenic target so as to avoid antigenic loss by mutation. Given that at face value the brother of regulator of imprinted sites (BORIS) transcription factor meets these criteria, we have developed a mutant variant of this molecule (mBORIS) that lacks tumorigenic ability, while retaining immunogenic epitopes that elicits responses against histologically irrelevant tumor cells. Here we compared vaccine strategies employing as an immunogen either mBORIS recombinant protein formulated in a strong Th1-type adjuvant, QuilA or DNA encoding this immunogen along with plasmids expressing interleukin (IL)12/IL18 molecular adjuvants. In both groups of vaccinated mice induction of tumor-specific immunity (antibody response, T-cell proliferation, cytokine production, T-cell cytotoxicity) as well as ability to inhibit growth of the aggressive breast cancer cell line and to prolong survival of vaccinated animals have been tested. We determined that DNA, but not recombinant protein vaccine, induced potent Th1-like T-cell recall responses that significantly inhibited tumor growth and prolongs the survival of vaccinated mice. These studies demonstrate that DNA immunization is superior to recombinant protein strategy and provide a clear guidance for clinical development of a cancer vaccine targeting what appears to be a universal tumor antigen.
Assuntos
Neoplasias da Mama/terapia , Vacinas Anticâncer/administração & dosagem , Proteínas de Ligação a DNA/genética , Terapia Genética/métodos , Imunoterapia/métodos , Vacinas de DNA/administração & dosagem , Adjuvantes Imunológicos/administração & dosagem , Animais , Neoplasias da Mama/imunologia , Vacinas Anticâncer/genética , Linhagem Celular Tumoral , Interferon gama/imunologia , Interleucina-12/genética , Interleucina-18/genética , Interleucina-4/imunologia , Camundongos , Mutação , Transplante de Neoplasias , Saponinas de Quilaia , Proteínas Recombinantes/administração & dosagem , Proteínas Recombinantes/imunologia , Saponinas/administração & dosagem , Células Th1/imunologia , Resultado do Tratamento , Vacinas de DNA/genéticaRESUMO
Previously, we generated human monoclonal antibodies using peripheral blood mononuclear cells from an asymptomatic human immunodeficiency virus type 1 (HIV-1)-seropositive donor. One of these monoclonal antibodies (designated clone 3, CL3) recognized 10 amino acids (GCSGKLICTT) within the immunodominant region (cluster I) of the transmembrane envelope glycoprotein gp41 and neutralized infection of target cells with different laboratory isolates. Because the epitope recognized by CL3 has two cysteine residues that could potentially produce a disulfide loop in gp41, we analyzed binding of our monoclonal antibody to the cyclic and linear motif of the peptide sequence IWGCSGKLICTTAVP (residues 600-614). The CL3 antibody did not bind to the synthetic cyclic peptide but did recognize the linear form. Two polyclonal rabbit sera against both the linear and cyclic peptides were then generated. Both antisera bound to viral glycoproteins gp41 and gp160, but neither sera neutralized HIV-1 laboratory isolates. Using a set of alanine-substituted IWGCSGKLICTTAV peptides, we analyzed binding of polyclonal antisera and CL3. The profile of binding of polyclonal antisera to these peptides was different from that of CL3 to the same peptides. This suggests that CL3 recognized a unique neutralizable core epitope, which was not immunogenic in either the cyclic or the linear IWGCSGKLICTTAVP peptides used as immunogens in the rabbits.
Assuntos
Antígenos HIV/imunologia , Proteína gp41 do Envelope de HIV/imunologia , HIV-1/imunologia , Epitopos Imunodominantes/imunologia , Sequência de Aminoácidos , Substituição de Aminoácidos , Animais , Anticorpos Monoclonais/imunologia , Especificidade de Anticorpos/imunologia , Linhagem Celular , Cisteína/imunologia , Cisteína/metabolismo , Dissulfetos/imunologia , Dissulfetos/metabolismo , Antígenos HIV/química , Proteína gp160 do Envelope de HIV/imunologia , Proteína gp41 do Envelope de HIV/química , Soropositividade para HIV/imunologia , Soropositividade para HIV/virologia , HIV-1/genética , HIV-1/fisiologia , Humanos , Soros Imunes/imunologia , Epitopos Imunodominantes/química , Dados de Sequência Molecular , Testes de Neutralização , Peptídeos Cíclicos/síntese química , Peptídeos Cíclicos/química , Peptídeos Cíclicos/imunologia , Coelhos , Replicação ViralRESUMO
Studies have indicated that professional APCs in the periphery, such as dendritic cells and macrophages, play an important role in initiating DNA vaccine-specific immune responses. To engineer the immune response induced by DNA vaccines in vivo we investigated the modulatory effects of codelivering growth factor genes for the hematopoietic APCs along with DNA vaccines. Specifically, we examined the effects on the antigen-specific immune responses following the codelivery of the gene expression cassettes for M-CSF, G-CSF, and GM-CSF along with HIV-1 DNA immunogen constructs. We observed that coimmunization with GM-CSF increased the antibody response and resulted in a significant enhancement of lymphoproliferative response. Furthermore, among all coinjection combinations, we found that M-CSF coinjections resulted in a high level of CTL enhancement. This enhancement of CTL responses observed from the coinjection with M-CSF was CD8+ T cell dependent and was associated with the presence of CD11c+ cells at the site of injection and with the antigen-specific induction of the beta-chemokine MIP-1beta, suggesting a role for this chemokine in CTL induction. These results suggest that hematopoietic growth factors should be further studied as potential adjuvants for in vivo modulators of immune responses.
Assuntos
Células Dendríticas/metabolismo , Vetores Genéticos/genética , Fator Estimulador de Colônias de Granulócitos/genética , Fator Estimulador de Colônias de Granulócitos e Macrófagos/genética , HIV-1/genética , Fator Estimulador de Colônias de Macrófagos/genética , Animais , Linfócitos T CD8-Positivos/metabolismo , Vacinas Anticâncer/farmacologia , Quimiocinas CC/biossíntese , Citomegalovirus/genética , Feminino , Citometria de Fluxo , Humanos , Interleucina-12/genética , Interleucina-4/genética , Fator Estimulador de Colônias de Macrófagos/fisiologia , Camundongos , Camundongos Endogâmicos BALB C , Músculos/patologia , Plasmídeos , Regiões Promotoras Genéticas , Linfócitos T Citotóxicos/metabolismo , Células Tumorais CultivadasRESUMO
Activation of T cells requires both TCR-specific ligation by direct contact with peptide Ag-MHC complexes and coligation of the B7 family of ligands through CD28/CTLA-4 on the T cell surface. We recently reported that coadministration of CD86 cDNA along with DNA encoding HIV-1 Ags i.m. dramatically increased Ag-specific CTL responses. We investigated whether the bone marrow-derived professional APCs or muscle cells were responsible for the enhancement of CTL responses following CD86 coadministration. Accordingly, we analyzed CTL induction in bone marrow chimeras. These chimeras are capable of generating functional viral-specific CTLs against vaccinia virus and therefore represent a useful model system to study APC/T cell function in vivo. In vaccinated chimeras, we observed that only CD86 + Ag + MHC class I results in 1) detectable CTLs following in vitro restimulation, 2) detectable direct CTLs, 3) enhanced IFN-gamma production in an Ag-specific manner, and 4) dramatic tissue invasion of T cells. These results support that CD86 plays a central role in CTL induction in vivo, enabling non-bone marrow-derived cells to prime CTLs, a property previously associated solely with bone marrow-derived APCs.
Assuntos
Antígenos CD/administração & dosagem , Antígenos CD/fisiologia , Citotoxicidade Imunológica , Epitopos de Linfócito T/imunologia , Antígenos H-2/imunologia , Glicoproteínas de Membrana/administração & dosagem , Glicoproteínas de Membrana/fisiologia , Linfócitos T Citotóxicos/imunologia , Animais , Antígenos CD/biossíntese , Antígenos CD/genética , Antígeno B7-1/biossíntese , Antígeno B7-1/genética , Antígeno B7-1/fisiologia , Antígeno B7-2 , Movimento Celular/imunologia , Citotoxicidade Imunológica/efeitos dos fármacos , Citotoxicidade Imunológica/genética , Feminino , Antígenos H-2/genética , Antígenos H-2/farmacologia , Proteína gp160 do Envelope de HIV/biossíntese , Proteína gp160 do Envelope de HIV/genética , Antígeno de Histocompatibilidade H-2D , Ativação Linfocitária/efeitos dos fármacos , Ativação Linfocitária/genética , Glicoproteínas de Membrana/biossíntese , Glicoproteínas de Membrana/genética , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Músculo Esquelético/imunologia , Músculo Esquelético/metabolismo , Músculo Esquelético/virologia , Engenharia de Proteínas , Quimera por Radiação , Células-Tronco/imunologia , Transfecção/imunologia , Microglobulina beta-2/genéticaRESUMO
The potential roles of adhesion molecules in the expansion of T cell-mediated immune responses in the periphery were examined using DNA immunogen constructs as model antigens. We coimmunized cDNA expression cassettes encoding the adhesion molecules intracellular adhesion molecule-1 (ICAM-1), lymphocyte function associated-3 (LFA-3), and vascular cell adhesion molecule-1 (VCAM-1) along with DNA immunogens, and we analyzed the resulting antigen-specific immune responses. We observed that antigen-specific T-cell responses can be enhanced by the coexpression of DNA immunogen and adhesion molecules ICAM-1 and LFA-3. Coexpression of ICAM-1 or LFA-3 molecules along with DNA immunogens resulted in a significant enhancement of T-helper cell proliferative responses. In addition, coimmunization with pCICAM-1 (and more moderately with pCLFA-3) resulted in a dramatic enhancement of CD8-restricted cytotoxic T-lymphocyte responses. Although VCAM-1 and ICAM-1 are similar in size, VCAM-1 coimmunization did not have any measurable effect on cell-mediated responses. These results suggest that ICAM-1 and LFA-3 provide direct T-cell costimulation. These observations are further supported by the finding that coinjection with ICAM-1 dramatically enhanced the level of interferon-gamma (IFN-gamma) and beta-chemokines macrophage inflammatory protein-1alpha (MIP-1alpha), MIP-1beta, and regulated on activation normal T-cell expression and secreted (RANTES) produced by stimulated T cells. Through comparative studies, we observed that ICAM-1/LFA-1 T-cell costimulatory pathways are independent of CD86/CD28 pathways and that they may synergistically expand T-cell responses in vivo.
Assuntos
Molécula 1 de Adesão Intercelular/imunologia , Ativação Linfocitária , Proteínas Inflamatórias de Macrófagos/biossíntese , Linfócitos T/imunologia , Vacinas contra a AIDS/imunologia , Adjuvantes Imunológicos , Animais , Antígenos CD/imunologia , Antígeno B7-1/imunologia , Antígeno B7-2 , Antígenos CD58/genética , Antígenos CD58/imunologia , Quimiocina CCL3 , Quimiocina CCL4 , Citotoxicidade Imunológica , Feminino , Proteínas de Fusão gag-pol/imunologia , HIV-1/imunologia , Humanos , Molécula 1 de Adesão Intercelular/genética , Interferon gama/biossíntese , Glicoproteínas de Membrana/imunologia , Camundongos , Camundongos Endogâmicos BALB C , Proteínas Recombinantes/imunologia , Linfócitos T Auxiliares-Indutores/imunologia , Vacinas de DNA/imunologia , Molécula 1 de Adesão de Célula Vascular/genética , Molécula 1 de Adesão de Célula Vascular/imunologiaRESUMO
Peptides may substitute for carbohydrates in reactions with carbohydrate-specific molecules. Recently, we found that peptides containing aromatic residues mimic mucin and histo-blood group related carbohydrate epitopes, eliciting polyclonal responses cross-reactive with bacterial and viral antigens that express these carbohydrate forms. These results demonstrate that peptides can function in in vivo and in vitro models as carbohydrate surrogate antigens. To further explore the nature of the antigenic and immunogenic properties of such mimotopes, synthetic peptides with aromatic amino acids were tested to delineate reactivity patterns with several anti-neolactoseries monoclonal antibodies (MAbs). These MAbs recognize biologically important conformations of the histo-blood group related Lewis antigens expressed on the surface of a variety of human cancers. Results by ELISA demonstrate that the MAbs can distinguish particular peptide motifs that include the sequences GGIYYPYDIYYPYDIYYPYD, GGIYWRYDIYWRYDIYWRYD and GGIYYRYDIYYRYDIYYRYD. Substitution of Arg by Pro diminished the reactivity of the anti-Lewis Y (LeY) MAb BR55-2. Binding of LeY to BR55-2 was inhibitable by the Arg containing peptides. Serum against all three peptides displayed reactivity with synthetic histo-blood group related antigen probes. Immunologic presentation of the peptides as multiple antigen peptides (MAPs) improved peptide ability to induce LeY specific immune responses. Serum bound to human tumor cells that preferentially expressed neolactoseries antigens, but not to normal tissues. Immunoprecipitation of human breast tumor cell lysates before and after treatment with tunicamycin confirmed serum carbohydrate binding. The anti-peptide sera mediated tumor cell killing by complement mediated cytotoxicity. These results indicate that mapping peptide epitopes with anti-carbohydrate antibodies can lend to defining antibody fine specificities that can go undetected by screening of carbohydrate antigens alone. In addition, these results confirm that peptides and carbohydrates can bind to the same antibody binding site and that peptides can structurally mimic salient features of carbohydrate epitopes.
Assuntos
Antígenos do Grupo Sanguíneo de Lewis/imunologia , Mimetismo Molecular/imunologia , Sequência de Aminoácidos , Animais , Anticorpos Monoclonais , Sequência de Carboidratos , Carboidratos/química , Carboidratos/imunologia , Epitopos/genética , Humanos , Antígenos do Grupo Sanguíneo de Lewis/química , Antígenos do Grupo Sanguíneo de Lewis/genética , Camundongos , Camundongos Endogâmicos BALB C , Mimetismo Molecular/genética , Dados de Sequência Molecular , Peptídeos/genética , Peptídeos/imunologia , Células Tumorais CultivadasRESUMO
DNA immunization has been investigated as a potential immunization strategy against infectious diseases and cancer. To enhance a DNA vaccine's ability to induce CTL response in vivo, we co-administered CD80 and CD86 expression cassettes along with HIV-1 immunogens. This manipulation resulted in a dramatic increase in MHC class I-restricted and CD8+ T-cell-dependent CTL responses in both mice and chimpanzees. This strategy of engineering vaccine producing cells to be more efficient T-cell activators could be an important tool for optimizing antigen-specific T-cell-mediated immune responses in the pursuit of more rationally designed vaccines and immune therapies.
Assuntos
Antígenos CD/genética , Antígenos CD/imunologia , Antígeno B7-1/genética , Antígeno B7-1/imunologia , Glicoproteínas de Membrana/genética , Glicoproteínas de Membrana/imunologia , Vacinas de DNA/genética , Vacinas de DNA/imunologia , Sequência de Aminoácidos , Animais , Apresentação de Antígeno , Antígenos CD/biossíntese , Antígeno B7-1/biossíntese , Antígeno B7-2 , Linfócitos T CD8-Positivos/imunologia , Clonagem Molecular , DNA Complementar/administração & dosagem , DNA Complementar/genética , DNA Complementar/metabolismo , Epitopos/imunologia , Antígenos HIV/genética , Antígenos HIV/imunologia , HIV-1/imunologia , Antígenos de Histocompatibilidade Classe I/imunologia , Ativação Linfocitária/imunologia , Linfocinas/biossíntese , Glicoproteínas de Membrana/biossíntese , Camundongos , Camundongos Endogâmicos BALB C , Dados de Sequência Molecular , Pan troglodytes , Linfócitos T Citotóxicos/imunologia , Linfócitos T Auxiliares-Indutores/imunologiaRESUMO
Immunization with nucleic acids has been shown to induce both antigen-specific cellular and humoral immune responses in vivo. We hypothesize that immunization with DNA could be enhanced by directing specific immune responses induced by the vaccine based on the differential correlates of protection known for a particular pathogen. Recently we and others reported that specific immune responses generated by DNA vaccine could be modulated by co-delivery of gene expression cassettes encoding for IL-12, granulocyte-macrophage colony-stimulating factor and the co-stimulatory molecule CD86. To further engineer the immune response in vivo, we investigated the induction and regulation of immune responses following the co-delivery of pro-inflammatory cytokine (IL-1 alpha, TNF-alpha, and TNF-beta), Th1 cytokine (IL-2, IL-12, IL-15, and IL-18), and Th2 cytokine (IL-4, IL-5 and IL-10) genes. We observed enhancement of antigen-specific humoral response with the co-delivery of Th2 cytokine genes IL-4, IL-5, and IL-10 as well as those of IL-2 and IL-18. A dramatic increase in antigen-specific T helper cell proliferation was seen with IL-2 and TNF-alpha gene co-injections. In addition, we observed a significant enhancement of the cytotoxic response with the co-administration of TNF-alpha and IL-15 genes with HIV-1 DNA immunogens. These increases in CTL response were both MHC class I restricted and CD8+ T cell dependent. Together with earlier reports on the utility of co-immunizing using immunologically important molecules together with DNA immunogens, we demonstrate the potential of this strategy as an important tool for the development of more rationally designed vaccines.
Assuntos
Vacinas contra a AIDS/imunologia , Citocinas/administração & dosagem , Vacinas de DNA/imunologia , Animais , Formação de Anticorpos , Linfócitos T CD8-Positivos/imunologia , Células Cultivadas , Citocinas/genética , Citotoxicidade Imunológica , Expressão Gênica , Anticorpos Anti-HIV/biossíntese , Camundongos , Camundongos Endogâmicos BALB C , Linfócitos T Citotóxicos/imunologia , Linfócitos T Auxiliares-Indutores/imunologia , Células Th1/imunologia , Células Th2/imunologiaRESUMO
The exact mechanism by which the human T cell leukemia viruses (HTLV) infects target cells remains unclear; although some molecules have been identified to be important in viral infection and entry. To investigate these phenomena, we generated a panel of monoclonal antibodies (MAb) against a B cell line (BJAB-WH) which is highly permissive for infection with HTLV. These MAb have been used to further characterize the membrane molecules important for HTLV infection. Three of these MAb designated 4.2.3, 3.3.10, and 11.2.3 were capable of inhibiting syncytium formation induced in human B and T cell lines (i.e., BJAB-WH and SupT-1, respectively) by co-culture with HTLV-I infected MT-2 cells. All of these MAbs immunoprecipitated a 80-85 kDa antigen from the lysates of metabolically labeled BJAB-WH but not from BJAB-CC/84, a noninfectible target cell. The binding of these MAb with different HTLV target cells was analyzed and compared with binding of polyclonal monospecific antisera to the same cell lines. A 80-85 kDa membrane glycoprotein was isolated with an immunoaffinity chromatographic column constructed with MAbs 4.2.3 and 3.3.10. This cellular antigen was capable of inhibiting HTLV I/MT-2 induced fusion. This is the first direct demonstration that a 80-85 kDa cellular glycoprotein is directly involved in HTLV I/II infection and syncytium formation.
Assuntos
Antígenos de Superfície/imunologia , Glicoproteínas/imunologia , Infecções por HTLV-I/imunologia , Anticorpos Monoclonais , Fusão Celular/imunologia , Infecções por HTLV-I/etiologia , Humanos , Receptores de Superfície Celular/imunologiaAssuntos
Vírus Linfotrópico T Tipo 1 Humano/imunologia , Plasmídeos/imunologia , Vacinação/métodos , Vacinas de DNA/imunologia , Vacinas Virais/imunologia , Animais , Desenho de Fármacos , Vírus Linfotrópico T Tipo 1 Humano/genética , Vírus Linfotrópico T Tipo 1 Humano/patogenicidade , Vírus Linfotrópico T Tipo 1 Humano/fisiologia , HumanosRESUMO
Nucleic acid immunization has been investigated as immunotherapy for infectious diseases as well as for treating specific types of cancers. In this approach, nucleic acid expression cassettes are directly inoculated into the host, whose transfected cells become the production source of novel and possibly immunologically foreign protein. We have developed a DNA vaccine construct which encodes for PSA by cloning a cDNA for PSA into a mammalian expression vector under control of a CMV promoter. We investigated and characterized the immunogenicity of PSA DNA expression cassettes in mice. PSA-specific immune responses induced in vivo by immunization were characterized by enzyme-linked immunosorbent assay (ELISA), T helper proliferation cytotoxic T lymphocyte (CTL), and flow cytometry assays. We observed a strong and persistent antibody response against PSA for at least 180 days following immunization. In addition, a significant T helper cell proliferation was observed against PSA protein. Using synthetic peptides spanning the PSA open frame, we identified four dominant T helper epitopes of PSA. Furthermore, immunization with PSA plasmid induced MHC Class I CD8+ T cell-restricted cytotoxic T lymphocyte response against tumor cell targets expressing PSA. The prostate represents a very specific functional organ critical for reproduction but not for the health and survival of the individual. Understanding the immunogenicity of PSA DNA immunization cassettes offers insight into the possible use of this tumor-associated antigen as a target for immunotherapy. These results demonstrate the ability of the genetic PSA to serve as a specific immune target capable of generating both humoral and cellular immune responses in vivo.
Assuntos
Vacinas Anticâncer/imunologia , Antígeno Prostático Específico/imunologia , Vacinas de DNA/imunologia , Animais , Anticorpos Antineoplásicos/imunologia , Vacinas Anticâncer/genética , Mapeamento de Epitopos , Citometria de Fluxo , Expressão Gênica , Células HeLa , Antígenos de Histocompatibilidade Classe I/imunologia , Humanos , Técnicas Imunoenzimáticas , Interferon gama/análise , Interleucina-4/análise , Camundongos , Camundongos Endogâmicos BALB C , Antígeno Prostático Específico/genética , Linfócitos T Citotóxicos/imunologia , Linfócitos T Auxiliares-Indutores/imunologia , Vacinas de DNA/genéticaRESUMO
The role of the immune response in controlling human immunodeficiency virus type 1 (HIV-1) replication is controversial. Immunotherapeutic strategies that have the ability to broaden immune responses might play a role in slowing disease progression. DNA immunization was studied as immunotherapy in infected chimpanzees. Two HIV-1-infected chimpanzees were vaccinated with DNA plasmid vaccines, one with plasmid pCMN160, which expresses the envelope glycoprotein of HIV-1MN and rev, and the other with a control plasmid. The chimpanzee immunized with pCMN160 demonstrated enhanced humoral responses. Virus load was monitored. Virus load in the chimpanzee receiving pCMN160 decreased at week 20 and has remained at background levels. The control chimpanzee was subsequently vaccinated with pCMN160. After immunization, the antibody responses increased and, as in the first animal, the virus load decreased. These results indicate the potential of the immune response to have a direct impact on HIV-1 replication in chimpanzees.
Assuntos
Produtos do Gene rev/genética , Proteína gp160 do Envelope de HIV/genética , Infecções por HIV/imunologia , Infecções por HIV/terapia , HIV-1 , Vacinas de DNA/uso terapêutico , Sequência de Aminoácidos , Animais , Antígenos CD28/imunologia , Linfócitos T CD8-Positivos/imunologia , Células Cultivadas , Técnicas de Cocultura , DNA Viral/análise , DNA Viral/genética , Produtos do Gene rev/imunologia , Anticorpos Anti-HIV/sangue , Anticorpos Anti-HIV/imunologia , Proteína gp160 do Envelope de HIV/imunologia , Infecções por HIV/virologia , HIV-1/fisiologia , Imunoterapia Ativa , Leucócitos Mononucleares/imunologia , Leucócitos Mononucleares/virologia , Contagem de Linfócitos , Dados de Sequência Molecular , Pan troglodytes , Peptídeos/genética , Peptídeos/imunologia , Plasmídeos , Reação em Cadeia da Polimerase , Proteínas Recombinantes/imunologia , Vacinas de DNA/administração & dosagem , Carga Viral , Produtos do Gene rev do Vírus da Imunodeficiência HumanaRESUMO
Cancer-related, mucin-type carbohydrate epitopes, principally mannose and sialo-syl residues, are expressed on the envelope protein gp 160 of the human immunodeficiency virus (HIV). Anticarbohydrate antibodies directed toward these and other carbohydrate epitopes are known to neutralize HIV-1 infection by cell-free virus. Carbohydrates, however, being T cell-independent antigens, typically elicit diminished immune responses. To overcome this potential draw back, we have examined the ability of peptides that mimic such epitopes to elicit immune responses that cross-react with carbohydrate structures. We report that mouse polyclonal antisera generated against peptides that mimic mucin-related carbohydrate epitopes have anti-HIV-1 activity. Generation of antibodies was not lr-gene restricted, as at least two different strains of mice. Balb/c (H-2d) and C57Bl/6 (H-2b), responded equally to the peptides. The antipeptide sera displayed neutralizing activity against HIV-I/MN and HIV-I/3B viral strains. This neutralization was as good as human anti-HIV sera. These results indicate that peptide mimics of carbohydrates provide a novel strategy for the further development of reagents that elicit immune responses to carbohydrate epitopes associated with many infectious organisms and tumor cells.
Assuntos
Epitopos/imunologia , Proteína gp160 do Envelope de HIV/imunologia , Infecções por HIV/terapia , HIV-1/imunologia , Oligopeptídeos/imunologia , Síndrome da Imunodeficiência Adquirida/terapia , Sequência de Aminoácidos , Animais , Formação de Anticorpos , Carboidratos/imunologia , Linhagem Celular , Antígenos H-2 , Anticorpos Anti-HIV/biossíntese , Anticorpos Anti-HIV/sangue , Proteína gp160 do Envelope de HIV/química , Humanos , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C57BL , Testes de Neutralização , Oligopeptídeos/química , Relação Estrutura-AtividadeRESUMO
The coat protein (CP) of alfalfa mosaic virus was used as a carrier molecule to express antigenic peptides from rabies virus and HIV. The antigens were separately cloned into the reading frame of alfalfa mosaic virus CP and placed under the control of the subgenomic promoter of tobacco mosaic virus CP in the 30BRz vector. The in vitro transcripts of recombinant virus with sequences encoding the antigenic peptides were synthesized from DNA constructs and used to inoculate tobacco plants. The plant-produced protein (virus particles) was purified and used for immunization of mice. Both antigens elicited specific virus-neutralizing antibodies in immunized mice.
Assuntos
Vacinas contra a AIDS , Alfamovirus/genética , Anticorpos Antivirais/biossíntese , Antígenos Virais/imunologia , Anticorpos Anti-HIV/biossíntese , Antígenos HIV/imunologia , HIV-1/imunologia , Vacina Antirrábica , Vírus da Raiva/imunologia , Vacinas Sintéticas , Sequência de Aminoácidos , Animais , Anticorpos Antivirais/sangue , Formação de Anticorpos , Antígenos Virais/biossíntese , Linfócitos B/imunologia , Sequência de Bases , Capsídeo/biossíntese , Linhagem Celular , Clonagem Molecular , Primers do DNA , Escherichia coli , Anticorpos Anti-HIV/sangue , Antígenos HIV/biossíntese , Vírus Linfotrópico T Tipo 1 Humano/imunologia , Humanos , Rim , Camundongos , Dados de Sequência Molecular , Testes de Neutralização , Regiões Promotoras Genéticas , Proteínas Recombinantes de Fusão/biossíntese , Proteínas Recombinantes de Fusão/imunologia , Linfócitos T/imunologia , Vírus do Mosaico do Tabaco/genética , Transcrição GênicaRESUMO
We have previously reported that the human immunodeficiency virus type 1 (HIV-1) regulatory gene vpr induces differentiation of rhabdomyosarcoma (embryonal muscle tumor cell line) cells, an effect that is accompanied by reduced proliferative capacity of the transfected cells. In this report, we examine the effect of Vpr expression on several different tumor cell lines derived from unique lineages. These tumor cells display different patterns of modulated oncogenes including both ras and p53 mutations. Here we demonstrate that the growth of tumor cells in vitro and in vivo is arrested by the expression of HIV-1 Vpr. Expression of Vpr in several human tumor cell lines upon transfection resulted in an accumulation of cells in the G2/M phase of cell cycle with altered cellular morphology, including an increase in adherence, and growth arrest, consistent with a differentiated phenotype. Vpr expression in B78/H1 cells results in a marked reduction in colony formation in vitro and an associated reduction in melanin synthesis by the cells. Vpr-transfected melanoma cells inoculated into syngenic C57BL/6 mice showed a markedly reduced ability to form tumors in vivo. These results suggest that this retroviral regulatory gene has broad tumor suppressor effects, likely mediated by transcriptional regulation of the state of the host cell.
Assuntos
Produtos do Gene vpr/fisiologia , Genes Supressores de Tumor/fisiologia , HIV-1 , Neoplasias Experimentais/patologia , Animais , Ciclo Celular/fisiologia , Divisão Celular , Linhagem Celular , Fibroblastos , Expressão Gênica , Produtos do Gene vpr/genética , Genes p53/fisiologia , Humanos , Neoplasias Pulmonares/secundário , Melaninas/biossíntese , Melanoma/metabolismo , Melanoma/patologia , Camundongos , Camundongos Endogâmicos C57BL , Neoplasias Experimentais/metabolismo , Oncogenes , Ratos , Transfecção , Células Tumorais Cultivadas , Produtos do Gene vpr do Vírus da Imunodeficiência HumanaRESUMO
Carbohydrate antigens have been identified as significant antigens in many human tumors either by analyzing antibodies in patients' sera or by using monoclonal antibodies of either mouse or human origin. Three carbohydrate epitopes present on cancer-associated mucins [sialyl-Lewis A (SLA), sialyl-Lewis X (SLX), and sialyl-Tn (STn)] may have functional significance in metastasis. Subsequently, these antigens are considered as targets for active specific immunotherapy. Carbohydrates, as T-cell-independent antigens, often elicit diminished immune responses. To overcome this drawback, carbohydrates are typically coupled to protein carriers to elicit immunoglobulin G (IgG) responses as opposed to low-affinity IgM responses, which often times accompanies carbohydrate-based immunizations. In addition, some complex carbohydrates are difficult to synthesize. This latter aspect is further magnified if one considers that clustering of epitopes on neoglycoproteins must be emulated in the synthesis process, leading to multiple presentation or tandem repeats of the synthetic carbohydrate immunogen. Here, we examine the hypothesis that peptides that mimic carbohydrates might be developed to induce immune responses that target and mediate the killing of tumor cells, particularly breast cancer cells in an adjuvant-type setting. We have found that carbohydrate-mimicking peptides retain carbohydrate-like conformations, inducing anti-carbohydrate immune responses against breast tumor cells and mediating their killing by a complement-dependent mechanism.
Assuntos
Adenocarcinoma/imunologia , Antígenos Glicosídicos Associados a Tumores/química , Mimetismo Molecular/imunologia , Peptídeos/química , Adenocarcinoma/química , Animais , Formação de Anticorpos , Antígenos de Bactérias/imunologia , Antígenos Glicosídicos Associados a Tumores/imunologia , Sobrevivência Celular , Ensaio de Imunoadsorção Enzimática , Citometria de Fluxo , Humanos , Camundongos , Neisseria meningitidis/imunologia , Peptídeos/imunologia , Polissacarídeos Bacterianos/química , Polissacarídeos Bacterianos/imunologia , Células Tumorais CultivadasRESUMO
We have previously reported on the generation of specific functional immune responses after inoculation of animals with expression vectors encoding HIV-1 genes. This article provides the details of the first application of this new technology to induce immune responses against HIV-2. This virus is molecularly and serologically distinct from HIV-1 and is in fact more closely related to the simian immunodeficiency virus (SIV). Anti-HIV-2 and SIV antibodies were induced in mice of three different haplotypes following a single intramuscular inoculation with an HIV-2/ROD envelope glycoprotein expression vector (pcEnv-2). Boosting of animals with pcEnv-2 induced both anti-HIV-2 neutralizing antibodies and T cell-proliferative responses against HIV-2 and SIVmac proteins. We compared the humoral and cellular immune responses of mice injected with pcEnv-2 and then boosted with either the homologous DNA construct or a recombinant Env protein. Animals boosted with pcEnv-2 generated B and T cell immune responses as strong as those of mice boosted with recombinant gp140 protein in adjuvant. Finally, cellular immune responses were significantly increased with the coadministration of pcEnv-2 and a plasmid expressing interleukin 12. We therefore conclude that DNA plasmid inoculation induces cross-reactive anti-HIV-2 and anti-SIVmac immune responses in mice. This technology should be further investigated as a potential vaccine component for this human pathogen.
Assuntos
Vacinas contra a AIDS/imunologia , DNA Viral/imunologia , Anticorpos Anti-HIV/imunologia , HIV-2/imunologia , Vírus da Imunodeficiência Símia/imunologia , Vacinas de DNA/imunologia , Vacinas Sintéticas/imunologia , Animais , Células COS , Linhagem Celular , Chlorocebus aethiops , Reações Cruzadas , Feminino , Anticorpos Anti-HIV/biossíntese , Humanos , Camundongos , Camundongos Endogâmicos AKR , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C57BL , Plasmídeos , Linfócitos T/imunologia , Células Tumorais CultivadasRESUMO
DNA inoculation has the potential to produce antigens in a native as well as a host-"customized" form for presentation to the immune system. As such this technology may have relevance for vaccine/immune therapeutic strategies for a variety of infectious pathogens. In rodents in vivo inoculation of plasmid expression vectors encoding HIV-1 gene products leads to production of HIV-1 antigens in vivo, resulting in the production of both cellular and humoral immune responses. In primates only preliminary studies of serology have been reported. Here we report further evaluation of this new technology as a method to induce humoral and particularly cellular immune responses against a human pathogen, the HIV-1 virus, in nonhuman primates. Following inoculation and boosting of animals with an HIV gp160 plasmid expression vector we observed the induction of neutralizing responses against two diverse HIV-1 isolates in 2 of 3 vaccinated animals. T cell proliferative responses to HIV antigens were also observed in all plasmid-inoculated animals and specific cross-reactive cytotoxic T lymphocyte responses were developed in vaccinated animals. This report establishes the ability of DNA inoculation to induce cellular immune responses in nonhuman primates and suggests that further investigation of this technology with regard to human vaccine or immune therapeutic development is therefore warranted.
Assuntos
Vacinas contra a AIDS/imunologia , DNA Viral/imunologia , Produtos do Gene env/imunologia , Antígenos HIV/imunologia , HIV-1/imunologia , Precursores de Proteínas/imunologia , Linfócitos T/imunologia , Animais , Formação de Anticorpos , Linhagem Celular , Genes Virais , Anticorpos Anti-HIV/biossíntese , Anticorpos Anti-HIV/imunologia , Antígenos HIV/biossíntese , Proteína gp160 do Envelope de HIV , HIV-1/fisiologia , Humanos , Imunidade Celular , Ativação Linfocitária , Macaca fascicularis , Masculino , Testes de Neutralização , Plasmídeos , Roedores , Linfócitos T Citotóxicos/imunologiaRESUMO
Vaccine design against HIV-1 is complicated both by the latent aspects of lentiviral infection and the diversity of the virus. The type of vaccine approach used is therefore likely to be critically important. In general, vaccination strategies have relied on the use of live attenuated material or inactivated/subunit preparations as specific immunogens. Each of these methodologies has advantages and disadvantages in terms of the elicitation of broad cellular and humoral immune responses. Although most success has been achieved with live attenuated vaccines, there is a conceptual safety concern associated with the use of these vaccines for the prevention of human infections. In contrast, subunit or killed vaccine preparations enjoy advantages in preparation and conceptual safety; however, their ability to elicit broad immunity is more limited. In theory, inoculation of a plasmid DNA that supports in vivo expression of proteins, and therefore presentation of the processed protein antigen to the immune system, could be used to combine the features of a subunit vaccine and a live attenuated vaccine. We have designed a strategy for intramuscular DNA inoculation to elicit humoral and cellular immune responses against expressed HIV antigens. Uptake and expression are significantly enhanced if DNA is administered in conjunction with the facilitating agent bupivacaine-HCl. Using this technique we have demonstrated functional cellular and humoral immune responses against the majority of HIV-1 encoded antigens in both rodents and non-human primates.
Assuntos
Vacinas contra a AIDS/administração & dosagem , Vacinas contra a AIDS/imunologia , DNA Viral/imunologia , HIV-1/imunologia , Animais , Proteínas de Fusão gag-pol/imunologia , Produtos do Gene env/imunologia , Proteína gp160 do Envelope de HIV , Humanos , Precursores de Proteínas/imunologia , Linfócitos T Citotóxicos/imunologiaRESUMO
There are a number of rheumatologic manifestations of human retroviral infections associated with human immunodeficiency virus type I (HIV-I) and the human T-cell leukemia virus type I (HTLV-I) including arthritis, Sjøgren's syndrome-like symptoms as well as other varied autoimmune phenomena. Infection with HTLV-1 may be directly involved in the etiology and/or pathogenesis of an arthritic condition similar to rheumatoid arthritis. We have been characterizing a new vaccination strategy against human retroviral infections, designated DNA inoculation. This procedure involves the intramuscular injection of DNA plasmids which express specific human retroviral antigens. This technique results in the development of humoral and cellular immune responses against these proteins. Specifically, this method has been successfully used to develop immune responses against HIV-I and HTLV-I. The availability of rat and rabbit infection models for HTLV-I, coupled with the successful development of immune responses in these animals after DNA inoculation with an HTLV-I envelope expressing plasmid, will allow the efficacy of this vaccination technique to be evaluated with protection against in vivo viral challenge as an endpoint.